Figure 2 Sources of data to characterize the ADPKD clinical phenotype

Slides:

Advertisements

Similar presentations

Clinical Section: Added Value of a Paper (Novelty, quality, solidity, timely, etc …) Number of patients (families): ranges from > 1 to N … Natural history.

Advertisements

Definitions and classification of office blood pressure levels (mmHg) Modified by ESC Guidelines 2013 CARDIOcheckAPP.

Dr Godfrey Grech University of Malta

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.

Status Epilepticus Presenting After Traumatic Brain Injury in Infants Kurz, J. E.1; Zelleke, T.1; Carpenter, J.1; Dean, N.2; Singh, J.1; Kadom, N.3; Gaillard,

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Figure 5 A layered approach to the follow-up of patients with acute kidney disease (AKD) Figure 5 | A layered approach to the follow-up of patients with.

Figure 2 The US Centers for Disease Control and

Figure 4 Time course of the development of physiological changes

Figure 6 Effects of adiponectin on podocyte function

Figure 4 The theoretical contribution of genetic and

Figure 3 Energy metabolism regulation, cardiovascular and bone disease in CKD Figure 3 | Energy metabolism regulation, cardiovascular and bone disease.

Figure 6 Approach to drug management in patients with acute kidney disease (AKD) Figure 6 | Approach to drug management in patients with acute kidney disease.

Figure 3 Angiotensin signalling in adiporenal crosstalk

Figure 4 Interactions between adipose, the microbiome and kidney

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Mechanisms of kidney injury in the setting of obesity

Nat. Rev. Neurol. doi: /nrneurol

Figure 5 Schematic illustration of different clinical trial designs

Figure 2 Proinflammatory mechanisms in CKD

Congestive Heart Failure in Elderly Patients

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Pathogenic mechanisms and pathways in ADPKD

Nat. Rev. Cardiol. doi: /nrcardio

Figure 1 The genomic nephrology workflow: genetic diagnosis and clinical application Figure 1 |The genomic nephrology workflow: genetic diagnosis and clinical.

Nat. Rev. Nephrol. doi: /nrneph

Figure 7 The efficacy of phosphate-binder therapy

Figure 1 Metabolic profiling as a tool for studying rheumatic diseases

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 5 Risk factor control in the intensive treatment group

Figure 2 The network of chronic diseases and their mutual influences

Figure 1 The burden of chronic kidney disease (CKD)

Moving Further with Medical Tailoring

Nat. Rev. Nephrol. doi: /nrneph

Figure 2 Podocyte dysfunction is a common feature of renal injury

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Speckle tracking echocardiography to

Nat. Rev. Urol. doi: /nrurol

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

Figure 3 Algorithm for the determination of the clinical

Figure 5 Potential roles of phosphate and fibroblast growth factor 23 (FGF-23) in the development of cardiovascular disease in patients with chronic kidney.

Figure 6 Schematic of an analysis of a new biopsy

Nat. Rev. Nephrol. doi: /nrneph

Figure 1 Changes in relative plasma volume (RPV)

Alexandra M. Dainis, and Euan A. Ashley BTS 2018;3:

Figure 5 Examples of biomarker-guided trials

Figure 4 The molecular configuration of the CD20 molecule

Nat. Rev. Neurol. doi: /nrneurol

Nat. Rev. Nephrol. doi: /nrneph

Nat. Rev. Cardiol. doi: /nrcardio

Nat. Rev. Nephrol. doi: /nrneph

the SNP profile using 26 prostate cancer GWAS risk SNPs

Nat. Rev. Nephrol. doi: /nrneph

Figure 6 Hypothetical effect of starting therapy for autosomal

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Enrichment strategies for clinical trials

Nat. Rev. Nephrol. doi: /nrneph

Figure 3 Preventive strategies for CSA-AKI

Figure 5 Schematic overview of a clinical decision-support

Figure 4 The relationship between the time-dependent changes in the expression of immunoglobulin, mast cell, acute kidney injury (AKI), and fibrillar collagen.

Figure 4 Intracellular distribution and

Figure 4 Radiogenomics analysis can reveal relationships

Figure 1 Overview of the imaging biomarker roadmap

Juan M. Lopez-Gomez, Eduardo Verde, Rafael Perez-Garcia

Figure 3 Determination of the primary site

(Case 5) Left ventricular hypertrophy—12-lead ECG demonstrating NSR with LVH. The ST segment depression in the lateral leads (I, aVl, V5, and V6) is seen.

Figure 1 Relationships between genetic variants, quantitative traits and diseases Figure 1 | Relationships between genetic variants, quantitative traits.

Diastolic dysfunction in sickle cell

Presentation transcript:

Figure 2 Sources of data to characterize the ADPKD clinical phenotype Figure 2 | Sources of data to characterize the ADPKD clinical phenotype. Beyond vital information obtained from analyses of a patient's medical and family history, molecular genetic and imaging techniques can be used to further characterize the current disease status and prognosis of a patient. Other modalities that can provide clinically relevant information include blood-pressure monitoring and analyses of bodily fluids for the presence of specific biomarkers. LVH, left ventricular hypertrophy. Lanktree, M. B. & Chapman, A. B. (2017) New treatment paradigms for ADPKD: moving towards precision medicine Nat. Rev. Nephrol. doi:10.1038/nrneph.2017.127